Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

NZ sharemarket dips as big stocks weigh despite KMD gains
Markets

NZ sharemarket dips as big stocks weigh despite KMD gains

The NZ sharemarket closed down, although KMD Brands lifted on a positive result.

Investor days to test gentailer plans for new build and firming
Markets

Investor days to test gentailer plans for new build and firming

Investors want answers on build delays, capital plans and Huntly’s future.

Argosy delivers strong first-half results
Economy

Argosy delivers strong first-half results

Earnings and net tangible asset value per share up. 

Asset Plus' first-half profit lower as Munroe Lane in focus
Economy

Asset Plus' first-half profit lower as Munroe Lane in focus

First-half net tangible assets per share down on the year.